Exciting data today by Dr. Tim Yap + Repare Therapeutics in #AACR2023 plenary session. Camonsertib, partnered with Roche, continues to show high promise for patients with ovarian and other cancers. 👏Drs Maria Koehler, Mike Zinda and their teams! #precisiononcology #syntheticlethality

Senior Scientist, David Gallo, will be speaking at The Society of Gynecologic Oncology of Canada’s 23rd Continuing Professional Development meeting to discuss the use of CRISPR-based screening to identify new targets within #gynecologiccancer. Register here: bit.ly/42cWbez

Today, we announced our first quarter 2023 financial results and provided a business update. Full press release with additional details: lnkd.in/e5CstKNe #precisiononcology #syntheticlethality $RPTX

A watershed Q for us as Roche activates clinical starts of camonsertib globally + our multiple portfolio advances, with lunresertib data coming up + 2 new clinical programs. More great progress from amazing Repare Therapeutics team + collaborators. #precisioncology #syntheticlethality

Repare’s management team is participating in a fireside chat at the Morgan Stanley Annual Global Healthcare Conference in NYC next week. We look forward to connecting in person! Click here to watch the webcast: tinyurl.com/frnzmtdv

Incredibly proud of this recognition of our work, the courage of the patients participating in our trials and the leadership, perseverance, dedication and innovation of the awesome, global team at @Repare and of our collaborators. #precisiononcology #syntheticlethality

Looking forward to sharing important new Repare Therapeutics data across multiple programs and achievements by the team, including a plenary talk by Dr Timothy Yap on the Lunre-Camo combination!

Apologies for the Friday pm call 😥 but AACR-NCI-EORTC selected our data for a plenary presentation during the day Friday.

The uninformed perception is that biotech success can be easy. Find a great drug, run a trial with a great result, get bought out! Join me on a thread that explores the Bellus journey and how hard the path to drug development success can really be. $BLU $XBI

We look forward to presenting positive, new clinical data from our lunresertib + camonsertib MYTHIC combination trial, which includes a more mature data cut (Sept vs June in abstract) of more patients treated at clinically relevant doses next Friday at #Targets23.

Be sure to join Repare Therapeutics live video webcast - which will feature additional updates from this week’s abstracts and highlight the significant potential we see for this combination - on Friday 10/13 at 5:30 p.m. ET: bit.ly/46AaNqk

In nearly 50 years of Harvard University affiliation, I have never been as disillusioned and alienated as I am today.

Exciting new data today in Repare Therapeutics lunre+camo combo, showing remarkable early efficacy signals and 50% RECIST response in 10 gyn patients at prelim RP2D and 60% OR in that initial group. Phenomenal new opportunity for patients & amazing work by the team and investigators!

First patient has been dosed with camonsertib in Roche's Phase II global TAPISTRY trial treating patients with unresectable, locally advanced or metastatic #solidtumors. We are grateful to patients and investigators who are part of our shared mission. lnkd.in/eJ4jy8g3

We need to be doing everything we can to turn Canada into the best place for entrepreneurs to build 🇨🇦 What's proposed in the federal budget will do the complete opposite. Innovators and entrepreneurs will suffer and their success will be penalized -- this is not a wealth tax,

Today, Chrystia Freeland is introducing a motion to increase the capital gains inclusion rate in Canada. This isn't a wealth tax — it's a tax on innovation and risk-taking. Investing in new products or ideas is inherently risky. Entrepreneurs need incentives, not penalties, to drive

Thrilled to have Foundation Medicine as a partner in helping us genomically match the patients who will most benefit from our new medicines! #precisiononcology #syntheticlethality

Excited to have Steven’s Stein’s wisdom and experience added to our Board today!